# NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer
Canonical URL: https://biopharmsignal.com/news/NGM/ngm-bio-announces-appointment-of-wendy-yeh-m-d-as-chief-medical-officer
Ticker: NGM
Company: NGM Biopharmaceuticals
Source: NGM Biopharmaceuticals
Published: 2025-02-04 12:00 EST
Original Source URL: https://ir.ngmbio.com
## Summary

Dr. Yeh will oversee the continued clinical development of NGM Bio’s key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc.

## Article Body
Dr. Yeh will oversee the continued clinical development of NGM Bio’s key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc.
## Recent Company News
- 2025-02-24 08:00 EST — [NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients](https://biopharmsignal.com/news/NGM/ngm-bio-announces-first-participant-dosed-in-emerald-phase-2-clinical-study-of-ngm120-for-the-treatment-of-hyperemesis-gravidarum-hg-in-pregnant-patients) — Source: NGM Biopharmaceuticals
- 2025-02-04 12:00 EST — [NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/NGM/ngm-bio-announces-appointment-of-wendy-yeh-m-d-as-chief-medical-officer) — Source: NGM Biopharmaceuticals
- 2024-12-19 12:01 EST — [NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate](https://biopharmsignal.com/news/NGM/ngm-bio-and-kdt-ventures-enter-into-worldwide-license-agreement-for-ngm313-a-phase-2-ready-fgfr1c-klotho-agonist-drug-candidate) — Source: NGM Biopharmaceuticals
- 2024-07-17 11:01 EST — [NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum](https://biopharmsignal.com/news/NGM/ngm-bio-announces-122-million-series-a-financing-to-initiate-registrational-trial-in-primary-sclerosing-cholangitis-and-fund-phase-2-trial-in-hyperemesis-gravidarum) — Source: NGM Biopharmaceuticals
- 2024-04-05 13:20 EST — [NGM Bio Announces Closing of Tender Offer](https://biopharmsignal.com/news/NGM/ngm-bio-announces-closing-of-tender-offer) — Source: NGM Biopharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)